Fibrotech is Granted US and Canadian Patents
News Mar 08, 2014
Fibrotech has announced that it has been granted patents in the USA and Canada relating to the Company’s proprietary novel anti-fibrotic compounds.
The US patent is entitled “Halogenated Analogues of Anti-Fibrotic Agents” and the Canadian patent is entitled “Therapeutic Compounds”. Both have been granted composition of matter claims.
Prof. Darren Kelly, CEO of Fibrotech commented: “We are poised to announce Phase I results for our lead product so the granting of these patents is timely and will help us greatly in ongoing partnering discussions.”
Fibrotech entered the clinic in 2013 with its lead product FT011 for diabetic nephropathy. Kidney failure in diabetes occurs as a result of kidney fibrosis (scarring). This fibrosis is in turn due to the long term damage from excessive sugar levels in the blood. The results from a Phase I trial of FT011 will shortly be released.
Professor Darren Kelly, CEO of Fibrotech will be attending BIOEurope Spring in Turin on 10th and 11th of March and will be happy to meet with interested journalists and other parties there.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018